Plain-English translation of NCT05639972 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach called E7 TCR-T cell therapy for people with advanced HPV-related cancers. Researchers take your own immune cells, engineer them in the lab to recognize and attack cancer cells, and then give them back to you along with medications to help them work. The goal is to see if this treatment can shrink tumors before you receive standard cancer care.
Many HPV-related cancers are hard to treat once they've advanced, and patients need better options. This medication represents a new approach—using your body's own immune system, trained to specifically target cancer cells—that doctors hope could improve outcomes for patients like you.
You likely qualify if…
You likely don't qualify if…
First, you'll have a procedure called apheresis to collect your immune cells (similar to donating blood). After one week, you'll receive chemotherapy drugs to prepare your body, followed by an infusion of your engineered cells and another medication called to boost their activity. You'll have follow-up visits at 3 and 6 weeks to monitor your response, with imaging scans at 6 weeks to see if tumors have shrunk. After that, you'll be referred back to your regular cancer doctor for standard treatment, and researchers will track your health for 2 to 5 years.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States